To whom it may concern

Dr. Stefan Dreiheller
Quality Unit / Regulatory Affairs

Date of issue: 11.02.2021

Doc.-No. EIP-0062
Revision 9

Change Control

MEGGLE Products:
- Lactose Monohydrate (Ph. Eur. / USP-NF / JP): CapsuLac® 60, FlowLac® 90, FlowLac® 100, GranuLac® 70, GranuLac® 80, GranuLac® 140, GranuLac® 200, GranuLac® 230, PrismaLac® 40, SacheLac® 80, SorboLac® 400, SpheroLac® 100, Tablettose® 70, Tablettose® 80, Tablettose® 100
- Lactose Monohydrate (USP-NF / Ph. Eur. / JP): Lactose monohydrate Low Endotoxin
- Inhaler Grade Lactose Monohydrate (USP-NF / Ph. Eur. / JP): InhaLac® 70, InhaLac® 120, InhaLac® 140, InhaLac® 150, InhaLac® 160, InhaLac® 230, InhaLac® 250, InhaLac® 251, InhaLac® 400, InhaLac® 500
- Co-processed excipients: Cellactose® 80, CombiLac®, MicroceLac® 100, RetaLac®, Reta M®, StarLac®

Change Control according to IPEC-Americas Significant Change Guide for Bulk Pharmaceutical Excipients is implemented.

The Change Control procedure includes an appropriate evaluation of customers' and authorities' information about the change. Quality Unit has the responsibility and authority for final approval of changes.

MEGGLE is responsible for customer and authority notification.

Best regards

MEGGLE GmbH & Co. KG
represented by MEGGLE Verwaltungs GmbH

i.V. Stefan Dreiheller
Dr. Stefan Dreiheller